MCID: HPT021
MIFTS: 76

Hepatitis

Categories: Gastrointestinal diseases, Endocrine diseases, Liver diseases, Genetic diseases, Rare diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 38 12 76 29 55 6 43 15 73
Chronic Persistent Hepatitis 12 55 73
Acute Hepatitis 12 29 73
Hepatitis, Chronic 44 73
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Chronic Hepatitis 12
Hepatitis Chronic 55
Hepatitis, Animal 73
Animal Hepatitis 12
Hepatitis a 73

Classifications:



Summaries for Hepatitis

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. Viruses cause most cases of hepatitis. The type of hepatitis is named for the virus that causes it; for example, hepatitis A, hepatitis B or hepatitis C. Drug or alcohol use can also cause hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver. Some people who have hepatitis have no symptoms. Others may have Loss of appetite Nausea and vomiting Diarrhea Dark-colored urine and pale bowel movements Stomach pain Jaundice, yellowing of skin and eyes Some forms of hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer. Sometimes hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to alcoholic hepatitis and hepatic encephalopathy, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Regulation of IFNA signaling and NF-kappaB Signaling. The drugs Zinc and rituximab have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotype is mortality/aging.

Wikipedia : 76 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1805)
# Related Disease Score Top Affiliating Genes
1 alcoholic hepatitis 34.6 GPT SLC17A5 TNF
2 hepatic encephalopathy 34.6 GPT SLC17A5 TNF
3 hepatitis a 34.3 AFP GPT HAVCR1 HAVCR2 IFNA2 TNF
4 hepatitis c virus 33.6 CD81 CLDN1 CLDN6 GPT HAVCR2 IFNL4
5 viral hepatitis 33.2 AFP GPT IFNA1 IFNA2 SEPSECS SLC17A5
6 hepatitis b 33.1 AFP GPT IFNA1 IFNA2 IFNAR2 LAMTOR5
7 liver cirrhosis 32.9 AFP GPT IFNA1 SLC17A5
8 fatty liver disease 32.8 GPT SLC17A5 TNF
9 hepatitis c 32.8 CD81 CLDN1 CLDN6 GPT IFNA1 IFNA2
10 liver disease 32.7 AFP GPT IFNA1 SEPSECS SLC17A5 TNF
11 cryoglobulinemia, familial mixed 31.7 IFNA1 IFNA2
12 nonalcoholic steatohepatitis 31.4 GPT SLC17A5 TNF
13 cholangitis 31.3 CLDN1 GPT TNF
14 obstructive jaundice 31.1 GPT SLC17A5 TNF
15 scrub typhus 30.5 GPT SLC17A5 TNF
16 opisthorchiasis 30.3 AFP GPT
17 kwashiorkor 30.2 GPT SLC17A5
18 paraquat poisoning 30.1 GPT SLC17A5
19 gastrointestinal system disease 30.1 AFP IFNA1 TNF
20 pyridoxine deficiency 30.0 GPT SLC17A5
21 kaposi sarcoma 29.4 IFNA1 IFNA2 TNF
22 autoimmune hepatitis 12.4
23 hepatic veno-occlusive disease 12.4
24 hepatitis d 12.4
25 hepatic venoocclusive disease with immunodeficiency 12.4
26 hepatic lipase deficiency 12.3
27 hepatitis e 12.3
28 congenital hepatic fibrosis 12.2
29 hepatic adenomas, familial 12.2
30 non-a-e hepatitis 12.2
31 renal-hepatic-pancreatic dysplasia 12.2
32 porphyria, acute hepatic 12.1
33 epstein-barr virus hepatitis 12.1
34 renal-hepatic-pancreatic dysplasia 2 12.1
35 hepatic fibrosis, severe due to schistosoma mansoni infection 12.1
36 granulomatous hepatitis 12.0
37 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.0
38 hepatic coma 12.0
39 hepatic flexure cancer 12.0
40 renal-hepatic-pancreatic dysplasia 1 12.0
41 drug-induced hepatitis 12.0
42 hepatic tuberculosis 12.0
43 fulminant viral hepatitis 12.0
44 hepatic infarction 11.9
45 hepatic angiomyolipoma 11.9
46 halothane hepatitis 11.9
47 hepatitis b vaccine, response to 11.9
48 acute liver failure 11.9
49 sclerosing hepatic carcinoma 11.9
50 hepatic vascular disease 11.9

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Chronic Myocardial Ischemia
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypothyroidism
Ischemic Heart Disease Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, pruritus, gastrointestinal gas, hepatocellular jaundice, lameness, animal

MGI Mouse Phenotypes related to Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 AFP CLDN1 CLDN6 HAVCR2 IFNAR2 LAMTOR5

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 829)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 23994
2
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
3
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
4
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
5
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
6
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
7
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
8
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 54-85-3 3767
9
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
10
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
11
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
12
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128-13-2 31401
13
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
14
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
15
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
16
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
17
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
18
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 44475014
19
Nevirapine Approved Phase 4,Phase 3,Phase 2,Not Applicable 129618-40-2 4463
20
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
21
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
22
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 561-27-3 5462328
23
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
24
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 30516-87-1 35370
25
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
26
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
28
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
29
Etanercept Approved, Investigational Phase 4,Phase 1,Phase 2 185243-69-0
30
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-24-8 5755
31
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
32
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
33
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154598-52-4 64139
34
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
35
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 9552079 2713
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
37
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
38
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
39
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
40
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
41
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
42
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
43
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
44
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
45
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-43-4 5816
46
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
47
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
48
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83-43-2 6741
49
Insulin Glargine Approved Phase 4 160337-95-1
50
Insulin glulisine Approved Phase 4 207748-29-6

Interventional clinical trials:

(show top 50) (show all 4426)
# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
5 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
6 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
7 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
8 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
9 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
10 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
11 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
12 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
13 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
14 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
15 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
16 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
17 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
18 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
19 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
20 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
21 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
22 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
23 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
24 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
25 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
26 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
27 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
28 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
29 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
30 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
31 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
32 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
33 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
34 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
35 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
36 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
37 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
38 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
39 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
40 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
41 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
42 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
43 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
44 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
45 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
46 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
47 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
48 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
49 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
50 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis, chronic

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Acute Hepatitis 29
2 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

41
Liver, T Cells, Testes, Kidney, Bone, B Cells, Brain

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 30440)
# Title Authors Year
1
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
2
Old and New Treatments for Pediatric Autoimmune Hepatitis. ( 29766815 )
2018
3
Rapid Remission of Graves' Hyperthyroidism Without Thionamides Under Immunosuppressive Treatment for Concomitant Autoimmune Hepatitis. ( 29336235 )
2018
4
Outbreak of Hepatitis A Virus Infection Among Adult Patients of a Mental Hospital-Los Angeles County, 2017 - CORRECTION. ( 29970205 )
2018
5
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )
2018
6
Complement factor 3 among children with hepatitis A: Assessment of bilirubin levels. ( 29371712 )
2018
7
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-I+ inhibitors in clinical practice. ( 29391775 )
2018
8
Solid-state [<sup>13</sup>C-<sup>15</sup>N] NMR resonance assignment of hepatitis B virus core protein. ( 29450824 )
2018
9
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
10
Immunoreaction-Mediated Aggregation of Gold Nanoparticles for Sensitive and Selective Assay of Hepatitis B Surface Antigen. ( 29448537 )
2018
11
A Cross-Sectional Study of Viral Hepatitis Perception among Residents from Southeast and North Regions of Brazil. ( 29364166 )
2018
12
A Case of Posterior Circulation Ischemic Stroke Caused by Heparin-Induced Thrombocytopenia after Detaining Hepatic Arterial Infusion Catheter. ( 29859863 )
2018
13
Complications of Liver Transplant in Adult Patients With the Hepatic Form of Wilson Disease. ( 29527989 )
2018
14
Knockout of microRNA-21 attenuates alcoholic hepatitis through VHL/NF-I_B signaling pathway in hepatic stellate cells. ( 29848019 )
2018
15
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
16
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
17
Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. ( 29277614 )
2018
18
Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. ( 29719598 )
2018
19
Can we reliably predict response to corticosteroid treatment in severe alcoholic hepatitis? ( 29881814 )
2018
20
Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. ( 29971609 )
2018
21
Treating chronic hepatitis E: when is enough enough? ( 29391359 )
2018
22
Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes. ( 29532736 )
2018
23
Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series. ( 29951369 )
2018
24
Hepatitis C virus infection in children in the era of direct-acting antiviral. ( 29962813 )
2018
25
Hepatic endometrial stromal sarcoma. ( 29843927 )
2018
26
Role of liver transplantation in severe alcoholic hepatitis. ( 29316778 )
2018
27
Proposal for a new subtype of the zoonotic genotype 3 Hepatitis E virus: HEV-3l. ( 29452164 )
2018
28
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
29
Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. ( 29975729 )
2018
30
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
31
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. ( 29034998 )
2018
32
Soluble Fgl2 restricts autoimmune hepatitis progression via suppressing Tc17 and conventional CD8+ T cell function. ( 29756667 )
2018
33
Hepatic glucose-6-phosphatase-I+ deficiency leads to metabolic reprogramming in glycogen storage disease type Ia. ( 29545180 )
2018
34
Origin and dispersal of Hepatitis E virus. ( 29410449 )
2018
35
A new marker for severity of alcoholic hepatitis. ( 29427735 )
2018
36
Detection of Astrovirus, Rotavirus C, and Hepatitis E Viral RNA in Adult and Juvenile Farmed Mink (<i>Neovison vison</i>). ( 29974054 )
2018
37
Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )
2018
38
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )
2018
39
Modification Patterns of Urinary Albumin Correlates With Serum Albumin and Outcome in Severe Alcoholic Hepatitis. ( 29369844 )
2018
40
Diagnosis of local hepatic tuberculosis through next-generation sequencing: Smarter, faster and better. ( 29759945 )
2018
41
Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. ( 29781346 )
2018
42
First detection and molecular characterization of hepatitis E virus in water from wastewater treatment plants in Portugal. ( 29936796 )
2018
43
Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MR imaging in patients with chronic liver disease. ( 29440620 )
2018
44
A case of Kaposi varicelliform eruption progressing to herpes simplex virus hepatitis in an immunocompetent patient. ( 29446473 )
2018
45
Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. ( 29972246 )
2018
46
Travel-associated hepatitis A in Europe, 2009 to 2015. ( 29871720 )
2018
47
Taurine treatment prevents derangement of the hepatic I^-glutamyl cycle and methylglyoxal metabolism in a mouse model of classical homocystinuria: regulatory crosstalk between thiol and sulfinic acid metabolism. ( 29101223 )
2018
48
Impact of patatin-like phospholipase domain containing 3 rs738409A G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. ( 29956823 )
2018
49
Hepatitis E virus in neurological disorders: a case of Parsonage-Turner syndrome. ( 29685043 )
2018
50
Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. ( 29326427 )
2018

Variations for Hepatitis

ClinVar genetic disease variations for Hepatitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
2 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275

Copy number variations for Hepatitis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

GO Terms for Hepatitis

Cellular components related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosomal membrane GO:0005765 8.92 LAMTOR5 LMBRD1 SCARB1 SLC17A5

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.8 IFNA1 IFNA2 IFNAR2 TNF
2 response to virus GO:0009615 9.63 IFNAR2 LAMTOR5 TNF
3 type I interferon signaling pathway GO:0060337 9.58 IFNA1 IFNA2 IFNAR2
4 cell-cell junction organization GO:0045216 9.56 CLDN1 CLDN6
5 defense response to virus GO:0051607 9.56 IFNA1 IFNA2 IFNAR2 IFNL4
6 T cell activation involved in immune response GO:0002286 9.55 IFNA1 IFNA2
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.54 IFNA1 IFNA2
8 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.52 CLDN1 CLDN6
9 positive regulation of chemokine production GO:0032722 9.51 HAVCR2 TNF
10 humoral immune response GO:0006959 9.5 IFNA1 IFNA2 TNF
11 natural killer cell activation involved in immune response GO:0002323 9.48 IFNA1 IFNA2
12 negative regulation of glucose import GO:0046325 9.43 LMBRD1 TNF
13 viral process GO:0016032 9.43 CD81 CLDN1 CLDN6 HAVCR1 LMBRD1 SCARB1
14 protein localization to lysosome GO:0061462 9.37 CD81 LAMTOR5
15 regulation of type I interferon-mediated signaling pathway GO:0060338 9.33 IFNA1 IFNA2 IFNAR2
16 viral entry into host cell GO:0046718 9.02 CD81 CLDN1 CLDN6 HAVCR1 SCARB1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNA1 IFNA2 IFNL4 TNF
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 virus receptor activity GO:0001618 9.02 CD81 CLDN1 CLDN6 HAVCR1 SCARB1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....